Search

everythinglearnresearchcommunity

for

Search:↓

User used sublingual minoxidil for 5 months and saw progress. Also used topical dutasteride, alfatradiol, tretinoin, and reduced oral finasteride dose.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

The user just4uman's experience with finasteride showing results after 9 months, and how they also use microneedling and minoxidil.

User tries Fluridil for hair loss after topical finasteride caused issues. Others doubt its effectiveness and cost.

The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

Silicone-based shampoos and conditioners may leave a layer on the scalp that could affect the absorption of topical hair loss treatments like Fluridil. The user is considering switching to silicone products to manage frizzy hair but is concerned about this potential issue.

The user is using finasteride 1mg every other day and seeks a topical solution to complement it, excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

Someone asked if Stemoxydine is effective for hair loss and if it improves hair growth or thickness. They also requested safe purchasing sources due to concerns about counterfeit products.

The conversation is about someone showing hair regrowth using liquid Minoxidil and vitamins, with others suggesting the addition of finasteride to maintain the improvement.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

Minoxidil combined with tretinoin may improve hair regrowth due to their synergistic effects. Using a gel with 0.025% tretinoin and antibiotics might still be beneficial.

A 43-year-old male has been using oral minoxidil, finasteride, and dutasteride for hair loss, with some stabilization and thin hair growth but no significant cosmetic improvement. He is considering increasing microneedling frequency and exploring other options, as he is concerned about the lack of terminal hair growth.

The conversation is about using alfatradiol for hair loss treatment. One user combined it with oral finasteride but noticed no significant difference.

The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.

The user is asking if observed hair growth is new or old hairs dying off. They mention using finasteride, minoxidil, and microneedling.

Finasteride can continue to improve hair loss for up to 10 years, with the best results seen when started early. Combining treatments like minoxidil, dermarolling, or RU58841 may enhance effectiveness.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.